라이트스트래티지(LITS) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

LITS

Lite Strategy Inc

7월 27일 4:00 PM ET (한국 7/28 05:00)

$0.98

-0.01 ▼ -1.20%

🌙 7월 28일 4:58 AM ET (한국 7/28 17:58)

$1.02

+0.04 ▲ +4.45%

라이트스트래티지(LITS) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$33M

스몰캡

P/E

배당수익률

없음

52주 위치

저점 +42% · 고점 -86%

애널리스트

매수

C+

Fundamental health

vs. Biotechnology· based on 2 axes

수익성

산출 불가 (적자)

성장

Top 43%

밸류에이션

데이터 부족

재무 안정

Top 49%

💰 Is this stock pricier than usual right now?

Compared to this company's own recent 1년 (not other companies).

Very cheap

Cheap

Typical

Pricey

Very pricey

Simply put — what you pay today to own $1 of this company's yearly earnings is 1원. Over the past 1년, it usually traded around 1원. Roughly in line with its own history.

Pricy doesn't mean bad — it means expectations are already baked in.· based on 1 profitable years

Index ⓘ	-	P/E ⓘ	-	EPS (ttm) ⓘ	-2.01	Insider Own ⓘ	12.18%	Shs Outstand ⓘ	35.2M	Perf Week ⓘ	-5.19%
Market Cap ⓘ	0.03B	Forward P/E ⓘ	-	EPS next Y ⓘ	-	Insider Trans ⓘ	0.61%	Shs Float ⓘ	29.9M	Perf Month ⓘ	19.49%
Enterprise Value ⓘ	0.03B	PEG ⓘ	-	EPS next Q ⓘ	-	Inst Own ⓘ	17.31%	Short Float ⓘ	0.4%	Perf Quarter ⓘ	-17.25%
Income ⓘ	-0.06B	P/S ⓘ	-	EPS this Y ⓘ	-	Inst Trans ⓘ	-14.18%	Short Ratio ⓘ	0.31	Perf Half Y ⓘ	-23.11%
Sales ⓘ	0.00B	P/B ⓘ	0.6	EPS next 5Y ⓘ	-	ROA ⓘ	-154.82%	Short Interest ⓘ	0.12M	Perf YTD ⓘ	-26.02%
Book/sh ⓘ	1.62	P/C ⓘ	4.41	EPS past 3/5Y ⓘ	37.89% 25.03%	ROE ⓘ	-159.26%	52W High ⓘ	-85.81% ($6.88)	Perf Year ⓘ	-85.51%
Cash/sh ⓘ	0.22	P/FCF ⓘ	-	Sales past 3/5Y ⓘ	-	ROIC ⓘ	-107.01%	52W Low ⓘ	41.77% ($0.69)	Perf 3Y ⓘ	-82.83%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	-	EPS Y/Y TTM ⓘ	57.61%	Gross Margin ⓘ	-	Volatility(W/M) ⓘ	6.19% 6.59%	Perf 5Y ⓘ	-97.53%
Dividend TTM ⓘ	-	EV/Sales ⓘ	-	Sales Y/Y TTM ⓘ	-100%	Oper. Margin ⓘ	-	ATR (14) ⓘ	0.06	Perf 10Y ⓘ	-95.45%
Dividend Ex-Date ⓘ	2023/11/16	Quick Ratio ⓘ	11.53	EPS Q/Q ⓘ	-71.8%	Profit Margin ⓘ	-	RSI (14) ⓘ	51.06	Recom ⓘ	2.33
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	11.53	Sales Q/Q ⓘ	-	SMA20 ⓘ	-0.28% ($0.98)	Beta ⓘ	0.2	Target Price ⓘ	$22.67
Payout ⓘ	-	Debt/Eq ⓘ	0	Earnings ⓘ	-	SMA50 ⓘ	3.09% ($0.95)	Rel Volume ⓘ	0.68	Prev Close ⓘ	$0.99
Employees ⓘ	4	LT Debt/Eq ⓘ	0	EPS/Sales Surpr. ⓘ	-	SMA200 ⓘ	-26.19% ($1.33)	Avg Volume(3M) ⓘ	0.38M	Price ⓘ	$0.98
IPO ⓘ	2003/12/18	Option/Short ⓘ	Yes/Yes			Trades ⓘ	548	Volume ⓘ	256,974	Change ⓘ	-1.2%

Quarterly earnings trend SEC filings · USD

24.6*

24.9

24.12

25.3

25.6*

25.9

25.12

26.3

Revenue Net income 최근 분기: 매출 $0M · 순이익 $-24M (YoY -821%)

* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Lite Strategy Inc (LITS) Investment Analysis

What kind of company is Lite Strategy Inc?

라이트스트래티지(LITS) 방어주

Healthcare · Biotechnology

Small-Cap — Low Volume, High Volatility

💎 This is the world's largest Litecoin (LTC) treasury company. Originally a biotech firm called MEI Pharma that developed cancer treatments, it pivoted its business strategy in 2025 to focus on acquiring Litecoin. It has raised $100 million in funding to aggressively purchase LTC and is headquartered in San Diego.

Learn more about Lite Strategy Inc →

Market Cap

$0.0B

Approx. KRW 0.0 trillion

⚖️ 0% of Samsung Electronics

Market Cap Rank5095

Employees4people

IPO2003/12/18

Current Price$0.98 ≈ 1,343원

NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🎯 Ex-div 2023년 11월 16일 (목)

Is it profitable?

Financially sound but profitability is low

Losses or thin margins — early-stage growth or weakening competitiveness

Profitability — How efficiently it makes money

ROE

Annual return earned on shareholders' equity (15%+ is strong)

-159.3%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROA

Annual earnings relative to total company assets

-154.8%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROIC

Return generated per dollar invested in the business

-107.0%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.00

✓ Very low debt

My positionTop 5%

Low range Average High range

Biotechnology Median 0.05

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

11.53

✓ 우수

My positionTop 25%

Low range Average High range

Biotechnology Median 5.75

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

11.53

✓ 우수

My positionTop 25%

Low range Average High range

Biotechnology Median 5.47

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook

Positive and negative signals are mixed

애널리스트 목표가

$22.67

현재가 대비 +2213.3%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Insufficient historical earnings data

No analyzable past earnings releases have been collected yet.

Is it growing?

Average Growth

Mid-range within the industry

📊 How much has it grown? (actual results)

Past 3-Year EPS

Actual average annual EPS growth over the past 3 years

+37.9%

양호

My positionMid-range

Low range Average High range

방어주 초소형주 Median 30.0% · Top 44%

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

+25.0%

양호

My positionMid-range

Low range Average High range

방어주 초소형주 Median 16.4% · Top 43%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -166%p below the market

LITS -97.5% · S&P 500 +68.3%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-165.9%p

Significantly behind the market

vs Health Care (XLV)

-122.0%p

Significantly behind the sector average

1-year basis

vs S&P 500

-101.5%p

Significantly behind the market

vs Health Care (XLV)

-105.2%p

Significantly behind the sector average

Rank among peers

5-year return Lower-Mid (lower 42%) Based on 245 peers

1-year return Bottom 17% Based on 315 peers

Current position within 52-week range

Low (-41.8%p) High (-85.8%p)

Current price is 41.8% above the 52-week low and 85.8% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-40.8%

Annualized volatility

74.1%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴

Current diagnosis · 2026-07-27

Downtrend zone

Current price $0.98 below the midline ($0.98). Normal downward flow. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟢

Current diagnosis · 2026-07-27

Bullish momentum holding

MACD 0.018 > Signal 0.017 in positive zone + Hist positive (+0.001). Trend in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢

Current diagnosis · 2026-07-27

Bullish zone

RSI 51.5 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 41.2.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry

Cheap on Vs. Assets

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

🏢 Vs. Assets Cheap

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

0.60x

✓ Very cheap

My positionTop 25%

Low range Average High range

Biotechnology 초소형주 median 1.35x · Top 22% — relatively cheap within the industry

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

Analyst target price (reference)

$22.67 vs. current price +2213.3%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Biotechnology 초소형주

Who owns it?

Ownership is broadly stable

Insider modest net buying +0.6% · Institutional net selling -14.2% · Short interest light 0.4%

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

+0.6%

Insiders net buying

🏦 Institutions (funds & investors)

-14.2%

Institutions large net selling

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 17.3%

Retail-led

Healthcare 초소형주 Median 14.2%

🧑‍💼 Insiders 12.2%

Founder/management large holders (strong skin-in-the-game)

Healthcare 초소형주 Median 16.1%

👤 Retail investors (estimated) 70.5%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

0.4%

Low — limited short-side pressure

Healthcare 초소형주 Median 3.9%

Past 90 days Little change

Short interest days to cover

0.3 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 35.2M주

Float (tradable shares) 29.9M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding LITS

ETFs with the highest weightings · 2 total shown

VTI

Vanguard Total Stock Market ETF

0.00%

$657.4B

VXF

Vanguard Extended Market Index ETF

0.00%

$30.4B

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
LITS This Stock	$33.2M	-	0.6 ▲	-159.26% ▼	-	-1.2%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 라이트스트래티지(LITS)?

라이트스트래티지(LITS) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of LITS?

The market cap of LITS is approximately $33M, ranking 5,095 within its sector.

What is the 52-week high and low for LITS?

LITS has recorded a 52-week high of $6.88 and a low of $0.69.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.